Is CELC or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Janux Therapeutics N/A -11.89% -11.13%

Does the media favor CELC or JANX?

In the previous week, Celcuity had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Celcuity and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Celcuity's score of 1.26 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ELVN or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Enliven Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Janux Therapeutics N/A -11.89% -11.13%

Does the media favor ELVN or JANX?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 4 mentions for Janux Therapeutics. Enliven Therapeutics' average media sentiment score of 1.56 beat Janux Therapeutics' score of 1.34 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Janux Therapeutics N/A -11.89% -11.13%

Does the media prefer RLAY or JANX?

In the previous week, Relay Therapeutics had 10 more articles in the media than Janux Therapeutics. MarketBeat recorded 14 mentions for Relay Therapeutics and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Relay Therapeutics' score of 1.00 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or TNGX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Tango Therapeutics N/A -25.75% -23.36%

Does the media refer more to JANX or TNGX?

In the previous week, Tango Therapeutics had 6 more articles in the media than Janux Therapeutics. MarketBeat recorded 10 mentions for Tango Therapeutics and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Tango Therapeutics' score of 1.27 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or AMLX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media refer more to JANX or AMLX?

In the previous week, Janux Therapeutics and Janux Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 1.34 beat Amylyx Pharmaceuticals' score of 1.31 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Janux Therapeutics (JANX) Competitors

$19.80 +0.10 (+0.51%)

As of 04:00 PM Eastern

Compare

JANX vs. CELC, ELVN, RLAY, TNGX, and AMLX

Should you buy Janux Therapeutics stock or one of its competitors? Janux Therapeutics's main competitors and comparable companies include Celcuity (CELC), Enliven Therapeutics (ELVN), Relay Therapeutics (RLAY), Tango Therapeutics (TNGX), and Amylyx Pharmaceuticals (AMLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Janux Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

63.3% of Celcuity shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 13.3% of Celcuity shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Celcuity presently has a consensus price target of $154.55, indicating a potential upside of 60.27%. Janux Therapeutics has a consensus price target of $36.46, indicating a potential upside of 84.15%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Celcuity has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market.

Janux Therapeutics has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Janux Therapeutics	$10M	121.06	-$113.62M	-$1.64	N/A

In the previous week, Celcuity had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Celcuity and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Celcuity's score of 1.26 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics' return on equity of -11.89% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Janux Therapeutics	N/A	-11.89%	-11.13%

Summary

Janux Therapeutics beats Celcuity on 11 of the 14 factors compared between the two stocks.

How does Janux Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Enliven Therapeutics currently has a consensus price target of $75.00, suggesting a potential upside of 25.73%. Janux Therapeutics has a consensus price target of $36.46, suggesting a potential upside of 84.15%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Enliven Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 4 mentions for Janux Therapeutics. Enliven Therapeutics' average media sentiment score of 1.56 beat Janux Therapeutics' score of 1.34 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has higher earnings, but lower revenue than Janux Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Janux Therapeutics	$10M	121.06	-$113.62M	-$1.64	N/A

Janux Therapeutics' return on equity of -11.89% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Janux Therapeutics	N/A	-11.89%	-11.13%

Enliven Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Janux Therapeutics beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Janux Therapeutics has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	271.39	-$276.48M	-$1.57	N/A
Janux Therapeutics	$10M	121.06	-$113.62M	-$1.64	N/A

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market.

In the previous week, Relay Therapeutics had 10 more articles in the media than Janux Therapeutics. MarketBeat recorded 14 mentions for Relay Therapeutics and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Relay Therapeutics' score of 1.00 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics currently has a consensus target price of $25.92, suggesting a potential upside of 36.33%. Janux Therapeutics has a consensus target price of $36.46, suggesting a potential upside of 84.15%. Given Janux Therapeutics' higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Janux Therapeutics' return on equity of -11.89% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Janux Therapeutics	N/A	-11.89%	-11.13%

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Janux Therapeutics beats Relay Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Tango Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Janux Therapeutics currently has a consensus price target of $36.46, suggesting a potential upside of 84.15%. Tango Therapeutics has a consensus price target of $43.46, suggesting a potential upside of 90.96%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Janux Therapeutics has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

In the previous week, Tango Therapeutics had 6 more articles in the media than Janux Therapeutics. MarketBeat recorded 10 mentions for Tango Therapeutics and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Tango Therapeutics' score of 1.27 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has higher revenue and earnings than Janux Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	121.06	-$113.62M	-$1.64	N/A
Tango Therapeutics	$62.38M	61.52	-$101.59M	-$0.85	N/A

Janux Therapeutics' return on equity of -11.89% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Tango Therapeutics	N/A	-25.75%	-23.36%

Summary

Janux Therapeutics and Tango Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Janux Therapeutics compare to Amylyx Pharmaceuticals?

Janux Therapeutics (NASDAQ:JANX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Janux Therapeutics and Janux Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 1.34 beat Amylyx Pharmaceuticals' score of 1.31 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

Janux Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	121.06	-$113.62M	-$1.64	N/A
Amylyx Pharmaceuticals	$87.37M	43.31	-$144.74M	-$1.43	N/A

Janux Therapeutics' return on equity of -11.89% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Janux Therapeutics currently has a consensus price target of $36.46, suggesting a potential upside of 84.15%. Amylyx Pharmaceuticals has a consensus price target of $36.50, suggesting a potential upside of 7.48%. Given Janux Therapeutics' higher possible upside, equities analysts plainly believe Janux Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Janux Therapeutics beats Amylyx Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JANX vs. The Competition

Export

Metric	Janux Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.20B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-12.07	12.66	273.28	25.38
Price / Sales	121.06	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.30	16.29	12.89	6.14
Net Income	-$113.62M	-$22.72M	$3.47B	$349.01M
7 Day Performance	5.43%	-1.37%	-0.33%	-1.47%
1 Month Performance	29.24%	11.07%	6.51%	2.47%
1 Year Performance	-14.06%	53.71%	25.19%	15.84%

Janux Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JANX Janux Therapeutics	2.4997 of 5 stars	$19.80 +0.5%	$36.46 +84.1%	-13.8%	$1.20B	$10M	N/A	30	High Trading Volume
CELC Celcuity	2.7776 of 5 stars	$89.06 +0.7%	$154.55 +73.5%	+79.5%	$4.33B	N/A	N/A	40	Positive News Analyst Forecast
ELVN Enliven Therapeutics	2.8503 of 5 stars	$57.89 +0.1%	$75.00 +29.6%	+182.5%	$4.24B	N/A	N/A	50	Positive News
RLAY Relay Therapeutics	2.9187 of 5 stars	$18.38 -2.1%	$25.92 +41.0%	+405.7%	$4.11B	$15.35M	N/A	330	Positive News
TNGX Tango Therapeutics	3.172 of 5 stars	$22.84 -2.1%	$43.46 +90.3%	+235.1%	$3.94B	$62.38M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Competitors

JANX vs. CELC, ELVN, RLAY, TNGX, and AMLX

How does Janux Therapeutics compare to Celcuity?

Summary

How does Janux Therapeutics compare to Enliven Therapeutics?

Summary

How does Janux Therapeutics compare to Relay Therapeutics?

Summary

How does Janux Therapeutics compare to Tango Therapeutics?

Summary

How does Janux Therapeutics compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Competitors

JANX vs. CELC, ELVN, RLAY, TNGX, and AMLX

How does Janux Therapeutics compare to Celcuity?

Do insiders and institutionals have more ownership in CELC or JANX?

Do analysts recommend CELC or JANX?

Which has more volatility and risk, CELC or JANX?

Which has higher earnings and valuation, CELC or JANX?

Does the media favor CELC or JANX?

Is CELC or JANX more profitable?

Summary

How does Janux Therapeutics compare to Enliven Therapeutics?

Do analysts prefer ELVN or JANX?

Does the media favor ELVN or JANX?

Which has stronger earnings and valuation, ELVN or JANX?

Is ELVN or JANX more profitable?

Which has more volatility & risk, ELVN or JANX?

Do insiders & institutionals hold more shares of ELVN or JANX?

Summary

How does Janux Therapeutics compare to Relay Therapeutics?

Which has preferable earnings and valuation, RLAY or JANX?

Which has more volatility and risk, RLAY or JANX?

Does the media prefer RLAY or JANX?

Do analysts prefer RLAY or JANX?

Is RLAY or JANX more profitable?

Do insiders and institutionals hold more shares of RLAY or JANX?

Summary

How does Janux Therapeutics compare to Tango Therapeutics?

Do insiders & institutionals have more ownership in JANX or TNGX?

Do analysts recommend JANX or TNGX?

Which has more risk and volatility, JANX or TNGX?

Does the media refer more to JANX or TNGX?

Which has preferable valuation & earnings, JANX or TNGX?

Is JANX or TNGX more profitable?

Summary

How does Janux Therapeutics compare to Amylyx Pharmaceuticals?

Does the media refer more to JANX or AMLX?

Which has more volatility and risk, JANX or AMLX?

Which has stronger valuation and earnings, JANX or AMLX?

Is JANX or AMLX more profitable?

Do analysts prefer JANX or AMLX?

Do insiders and institutionals believe in JANX or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools